Swiss Biotech Day shows great biopharma ambitions
The Swiss biopharmaceutical industry is on the verge of record growth: This was demonstrated at the live Swiss Biotech Day in Basel.
ADVERTISEMENT
About Thomas Gabrielczyk
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 2152 entries already.
Entries by Thomas Gabrielczyk
EuropaBio lobbies for better Orphan Drug rules
EuropaBio has responded to the European Commission’s public consultation on the Orphan Medicinal Products (OMPs) and Paediatrics Regulations.
Call for pull incentives to get started
With new backing from large pharma, rising investors interest, and new incubators on stage, the AMR community is now urging policy makers worldwide to bring pull incentives into reality.
Cardior bags €64m in Series B Financing
Cardior Pharmaceuticals GmbH is funding a Phase II trial with lead candidate CDR132L against mi-R132-induced heart failure.
ERS Genomics and Cellular Engineering Technologies collaborating
ERS Genomics and Cellular Engineering Technologies have entered into a CRISPR-Cas9 license agreement.
Visus Therapeutics cashes in €20m from LSP
Visus Therapeutics has baged a €20m stock financing to advance development of Brimochol for presbyopia
British drug developer Mission Therapeutics plc earns $20m milestone
British drug developer Mission Therapeutics plc has bagged a $20m milestone payment from Abbvie within the companies’ neurodegenerative disease collaboration.
Bayer takes over Vividion
The big pharma company is shelling out US$1.5bn in the acquisition of US screening specialist Vividion Therapeutics.
Spectricity raises €14m in Series B round
Belgian semiconductor specialist Spectricity BV has baged €14m to speed up the development of mobile hyperspectral sensors for medical applications.